Silver
Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics companies. Information gained from diagnostic tests is responsible for 70% of all medical decisions. We are proud to support over one million of these tests every day, impacting over 800,000 patients. Because Every Test Is A Life.™ Who We Are : Ortho Clinical Diagnostics is a leading global provider of in vitro diagnostics. We have an established track record for providing high-quality products and services to the global clinical laboratory and immunohematology communities. We provide hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate and reliable. Our customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs. Our Story : From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. Responsibility : Protecting the environment and advancing sustainability go hand-in-hand with our purpose of improving and saving lives through diagnostics. With a focus on innovation, commercial excellence and operational efficiency, our global leadership is relentless in its dedication to supporting customers and the patients they serve. Ortho History Y2021 : Ortho Goes Public Ortho began trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol "OCDX". Ortho Care™ was recognized by the Stevie Awards for Exceptional Customer Service for the fifth years in a row. Ortho Clinical Diagnostics was recognized with MedTech’s 2020 Outstanding Contribution to the Bio/Med Industry Award for its COVID-19 Testing Solutions. Y2020 : Ortho Launches VITROS® COVID-19 Testing Solutions Ortho launched the first high-volume antibody and antigen tests authorized by the U.S. Food and Drug Administration. The company’s COVID-19 solutions for mass-scale testing include two COVID-19 antibody tests — Total and IgG — both of which have FDA EUA and CE Mark, and an antigen test. VITROS® XT Solutions Win Prestigious Global Edison Award for Innovation ORTHO Optix™ Reader Completes Transfusion Medicine Portfolio. ORTHO Optix™ Reader becomes available in CE Mark countries. VITROS® XT 3400 Chemistry System Enhances Its VITROS® XT Solutions. Solutions offer labs faster, more accurate results and trusted system reliability to ensure better patient outcomes. Y2019 : VITROS® XT MicroSlides (CE Mark) VITROS® XT Chemistry Product Slides (FDA) Multi-test technology allows labs to run two frequently ordered tests simultaneously on one slide. VITROS® High Sensitivity Troponin I assay gets CE Mark Y2014 : The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson. Ortho Clinical Diagnostics receives CE Mark for ORTHO VISION™ Analyzer, making it commercially available in Europe, Japan and Australia. Y2001 : Ortho Clinical Diagnostics becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests, on the VITROS® ECi Immunodiagnostic System (for diagnostic use only; not for blood screening). Ortho Clinical Diagnostics develops Ortho trak-C™, the world’s first branded “Total HCV Core Antigen” test designed to provide reliable measures of HCV viremia. Y1989 : Ortho Products introduces first test for the detection of antibodies to hepatitis C Y1939 : Ortho Products, Inc is formed Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson.
The world is digitizing rapidly to deliver enhanced patient care and satisfaction, more effective data, and increased efficiency. And your Lab is no exception. That is why Ortho is introducing the next generation in Clinical Chemistry solutions, Digital Chemistry. Through Digital Chemistry, Ortho is reimagining the power of technology throughout your lab and providing you with the confidence to meet the needs of patients today and the knowledge you are prepared for the demands of tomorrow. The new VITROS® XT Systems utilize digital chemistry technology which enables the use of imaging algorithms to improve chemistry results. Its heart is our Digital Imaging System, the breakthrough in detection technology that replaces the analogue photometer and produces significantly more detail for each MicroSlide reaction. Digital analysis is performed using complex imaging algorithms which reduces errors and improves result quality. These algorithms identify the exact dimensions of the reaction zone on a MicroSlide, improving sample dispensing and reducing probe errors even detecting smaller sample volumes. When you add VITROS® digital INTELLICHECK®’s precise image algorithms for clot and bubble detection and VI VITROS® MicroSensor’s quantitative analysis of sample integrity, you get a vast reduction in errors and repeat testing. All these enhancements have been developed with your patients in mind. Optimizing the sample read area has an important patient benefit: reducing sample volume to an average of 3.8uL. This can improve the patient experience, particularly for populations whose sample is more precious. The new VITROS® XT Chemistry Products Slides have been developed for use on the VITROS® XT Systems. XT MicroSlides with dual test capability are intended to reduce sample size and enhance operational efficiency while maintaining analytical performance versus the conventional single slide test. Due to small sample volume, the size of the MicroSlide region available for optimum analytical measurement is reduced.
D-
Booth No.